Land: Australien
Sprache: Englisch
Quelle: Department of Health (Therapeutic Goods Administration)
Influenza virus haemagglutinin
Seqirus Pty Ltd
Influenza virus haemagglutinin
Registered
AGRIPPAL ® 2015 _Inactivated Influenza Vaccine (surface antigen)_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Agrippal vaccine. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. The information in this leaflet was last updated on the date listed on the final page. More recent information on the medicine may be available. YOU SHOULD ENSURE THAT YOU SPEAK TO YOUR PHARMACIST OR DOCTOR TO OBTAIN THE MOST UP TO DATE INFORMATION ON THE VACCINE. YOU CAN ALSO DOWNLOAD THE MOST UP TO DATE LEAFLET FROM WWW.NOVARTIS.COM.AU. Those updates may contain important information about the medicine and its use of which you should be aware. All medicines, including vaccines, have risks and benefits. Your doctor considers the risks of you or your child having Agrippal vaccine and the benefits he/she expect it will have. IF YOU HAVE ANY CONCERNS ABOUT THIS VACCINE, ASK YOUR DOCTOR, NURSE OR PHARMACIST. KEEP THIS LEAFLET. You may need to read it again. WHAT AGRIPPAL VACCINE IS USED FOR Agrippal vaccine helps prevent influenza, often called the flu. Influenza is caused by infection with specific influenza viruses. New types of influenza virus can appear each year. Agrippal vaccine contains strains of three different types of influenza virus. Each year the Australian Influenza Vaccine Committee and the New Zealand Ministry of Health decide which three types of virus are most suitable. Vaccination against influenza helps prevent infection with influenza and to control the spread of the disease. The virus in the vaccine is inactivated. Therefore the vaccine will not give you or your child the flu. Note: the vaccine will not protect you or your child from the other influenza viruses that Agrippal vaccine does not contain. It will not protect you from other types of influenza virus or from infections with other agents causing flu-like symptoms (such as the common cold). Agrippal vaccine is available only with a doct Lesen Sie das vollständige Dokument
Agr271114i.doc Page 1 of 6 AGRIPPAL ® 2015 NAME OF MEDICINE Inactivated Influenza Vaccine (surface antigen) DESCRIPTION Agrippal is a clear colourless suspension for injection. It is an egg-grown, inactivated influenza virus vaccine based on isolated surface antigens of A and B strains of influenza virus. The antigen composition and strains for the 2015 influenza season corresponds to the following types: A/California/7/2009 (H1N1)– like strain; A/Switzerland/9715293/2013 (H3N2)-like strain ; and B/Phuket/3073/2013-like strain The type and amount of viral antigens in Agrippal conform to the requirements of the Australian Influenza Vaccine Committee (AIVC) and the New Zealand Ministry of Health for the winter of 2015. The strains chosen for vaccine manufacture are endorsed by the AIVC as being antigenically equivalent to the reference virus. Each 0.5 mL vaccine dose contains 15µg haemagglutinin of each of the recommended strains. The vaccine preparation also contains Sodium chloride 4.0 mg, Potassium chloride 0.1 mg, Potassium dihydrogen phosphate 0.1 mg, Sodium phosphate-dibasic 0.66 mg, Magnesium chloride 0.05 mg, Calcium chloride 0.06 mg and Water for Injections to 0.5 mL. The vaccine may contain residues of the following substances: eggs, chicken proteins, kanamycin sulfate, neomycin sulfate, sodium citrate, barium sulfate, formaldehyde, sucrose, cetrimonium bromide (CTAB), polysorbate 80 and less than 0.2 µg of ovalbumin per 0.5 mL dose. PHARMACOLOGY Agrippal induces humoral antibodies against haemagglutinins, the surface antigens of the virus. These antibodies neutralize influenza viruses and are important in the prevention of natural infections. Seroprotection is generally obtained within 2 to 3 weeks. The duration of postvaccinal immunity to homologous strains or to strains closely related to the vaccine strains varies but is usually 6-12 months. Influenza viral strains undergo antigenic changes from year to year. Therefore the antigen component of Agrippal is revised for every flu season and annual v Lesen Sie das vollständige Dokument